百济神州(北京)生物科技有限公司

010-58958000

01058958000

BeiGene is a publically traded (BGNE, NASDAQ), globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. We have a global team of over 200 individuals, including over 150 scientists and clinicians, and a world-renowned scientific advisory board, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world. Our clinical pipeline is comprised of novel oral small molecules and monoclonal antibodies (mAb) for cancer, including an anti-PD-1 monoclonal antibody, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a best-in-class PARP inhibitor, and a variety of combination clinical studies. In addition, our robust preclinical programs are expected to generate more small molecule and mAb drugs for clinical development in coming years. For more information, please visit our website at www.beigene.com.